These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25925979)

  • 1. Effects of the Rho-kinase inhibitor, fasudil, on pulmonary hypertension.
    Odagiri K; Watanabe H
    Circ J; 2015; 79(6):1213-4. PubMed ID: 25925979
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects.
    Xiao JW; Zhu XY; Wang QG; Zhang DZ; Cui CS; Zhang P; Chen HY; Meng LL
    Circ J; 2015; 79(6):1342-8. PubMed ID: 25797071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease.
    Li F; Xia W; Yuan S; Sun R
    Pediatr Cardiol; 2009 Apr; 30(3):363-6. PubMed ID: 18953591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of the Rho-kinase pathway in pulmonary arterial hypertension].
    Fukumoto Y
    Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):178-81. PubMed ID: 24717605
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects of intervention with Rho kinase inhibitor fasudil on rats with hypoxic pulmonary hypertension].
    Sun XZ; Wang DW; Li J
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):946-7. PubMed ID: 17254468
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.
    Fukumoto Y; Matoba T; Ito A; Tanaka H; Kishi T; Hayashidani S; Abe K; Takeshita A; Shimokawa H
    Heart; 2005 Mar; 91(3):391-2. PubMed ID: 15710736
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.
    Fujita H; Fukumoto Y; Saji K; Sugimura K; Demachi J; Nawata J; Shimokawa H
    Heart Vessels; 2010 Mar; 25(2):144-9. PubMed ID: 20339976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of Rho kinase inhibitors for pulmonary arterial hypertension].
    Seto M
    Nihon Yakurigaku Zasshi; 2012 Jun; 139(6):251-5. PubMed ID: 22728987
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fasudil(Rho-kinase inhibitor)].
    Fukumoto Y
    Nihon Rinsho; 2011 Nov; 69 Suppl 9():402-7. PubMed ID: 22724237
    [No Abstract]   [Full Text] [Related]  

  • 10. Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
    Dai ZK; Wu BN; Chen IC; Chai CY; Wu JR; Chou SH; Yeh JL; Chen IJ; Tan MS
    Pediatr Pulmonol; 2011 Jan; 46(1):45-59. PubMed ID: 20717937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new class of drug for pulmonary arterial hypertension. Can a Rho-kinase inhibitor break the stagnation in treating it?
    Miyagawa K; Emoto N
    Circ J; 2013; 77(10):2477-8. PubMed ID: 23934390
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.
    Hanson SFL; Terry MH; Moretta DT; Power GG; Wilson SM; Alam F; Ahsan F; Blood AB; Giri PC
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):472-480. PubMed ID: 29756460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.
    Fukumoto Y; Tawara S; Shimokawa H
    Tohoku J Exp Med; 2007 Apr; 211(4):309-20. PubMed ID: 17409670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.
    Raja SG
    Recent Pat Cardiovasc Drug Discov; 2012 Aug; 7(2):100-4. PubMed ID: 22670803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats.
    Sun XZ; Tian XY; Wang DW; Li J
    Eur Rev Med Pharmacol Sci; 2014; 18(7):959-64. PubMed ID: 24763873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rho-kinase inhibitors].
    Seto M; Asano T
    Nihon Yakurigaku Zasshi; 2011 Sep; 138(3):112-6. PubMed ID: 21908938
    [No Abstract]   [Full Text] [Related]  

  • 17. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
    Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
    Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.
    Gupta V; Gupta N; Shaik IH; Mehvar R; McMurtry IF; Oka M; Nozik-Grayck E; Komatsu M; Ahsan F
    J Control Release; 2013 Apr; 167(2):189-99. PubMed ID: 23353807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of fasudil in patients with high-altitude pulmonary hypertension.
    Kojonazarov B; Myrzaakhmatova A; Sooronbaev T; Ishizaki T; Aldashev A
    Eur Respir J; 2012 Feb; 39(2):496-8. PubMed ID: 22298615
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
    Jiang BH; Tawara S; Abe K; Takaki A; Fukumoto Y; Shimokawa H
    J Cardiovasc Pharmacol; 2007 Feb; 49(2):85-9. PubMed ID: 17312448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.